Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 20, 2023 06:55 ET | Source: Synlogic, Inc.

Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the...
March 07, 2023 06:57 ET | Source: Synlogic, Inc.

Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

– Podium presentation on Phase 2 phenylketonuria (PKU) data – – Poster presentations on Phase 1 homocystinuria (HCU) data and HCU preclinical data – CAMBRIDGE, Mass., March 07, 2023 (GLOBE...
January 19, 2023 06:58 ET | Source: Synlogic, Inc.

Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)

CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that SYNB1934 was granted...
January 05, 2023 06:58 ET | Source: Synlogic, Inc.

Synlogic Provides Corporate Update and Outlook for 2023

Pivotal Phase 3 for SYNB1934 in phenylketonuria (PKU) to initiate in H1 2023 Rare Pediatric Disease Designation received for SYNB1353 for homocystinuria (HCU) Cash runway expected into H2 2024 ...
October 18, 2022 06:59 ET | Source: Synlogic, Inc.

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3

Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population Consistent, positive measures of...
May 24, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria

CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
April 26, 2022 11:24 ET | Source: The Rosen Law Firm PA

FIXX NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Homology Medicines, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FIXX

NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June...
March 31, 2022 17:15 ET | Source: The Rosen Law Firm PA

ROSEN, A LONGSTANDING LAW FIRM, Encourages Homology Medicines, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FIXX

NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
December 07, 2021 20:00 ET | Source: DelveInsight Business Research LLP

Phenylketonuria Pipeline Shows Rapid Progress in Clinical Trials | DelveInsight

Los Angeles, USA, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Phenylketonuria Pipeline Shows Rapid Progress in Clinical Trials | DelveInsight There are approximately 15+ key companies developing the...
July 07, 2021 05:00 ET | Source: Global Market Insights, Inc

Prenatal and New-born Genetic Testing Market revenue to cross USD 9.5 Bn by 2027: Global Market Insights Inc.

Selbyville, Delaware, July 07, 2021 (GLOBE NEWSWIRE) -- According to latest report “Prenatal and New-born Genetic Testing Market by Technology (Screening, Diagnostic), Disease (Downs Syndrome,...